You are here: Industry Insights > NSCLC

News List

CStone announces first prescriptions of precision therapy GAVRETO® (pralsetinib) issued across China for the treatment of adults with locally advanced or metastatic RET fusion-positive non-small cell prnasia
June 21, 2021
GAVRETO® (pralsetinib), a precision therapy discovered by CStone Pharmaceuticals' partner Blueprint Medicines, had the first batch of prescriptions issued at Guangdong Province People's Hospital and around 100 other hospitals across China.
Harbour BioMed Announces Dosing of First Patient of Next-Generation Anti-CTLA-4 Antibody in Combination with PD-1 Antibody in Patients with NSCLC prnasia
June 17, 2021
Harbour BioMed today announced the dosing of the first patient of HBM4003 in patients with advanced non-small cell lung cancer in its open phase I clinical study.
Imfinzi increases five year survival to 43 percent in Stage III lung cancer trial europeanpharmaceuticalreview
June 09, 2021
New data shows AstraZeneca’s Imfinzi (durvalumab) achieved an unprecedented five year survival rate of over 40 percent in patients with Stage III non-small cell lung cancer.
NICE recommends Tecentriq for first-line NSCLC pharmatimes
June 09, 2021
The UK National Institute for Health and Care Excellence (NICE) has recommended Roche’s Tecentriq (atezolizumab) monotherapy for untreated metastatic non-small cell lung cancer (NSCLC).
Amgen’s KRAS inhibitor Lumakras scores positive overall survival data pharmatimes
June 08, 2021
Amgen has presented new data on overall survival (OS) for its KRAS inhibitor Lumakras in previously treated non-small cell lung cancer (NSCLC) at the 2021 American Society of Clinical Oncology (ASCO) annual meeting.
Imfinzi Demonstrates Unprecedented Survival in Lung Cancer americanpharmaceuticalreview
June 08, 2021
The PACIFIC Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) demonstrated a sustained, clinically meaningful overall survival (OS) and progression-free survival (PFS) benefit at five years in patients with unresectable ...
Alphamab Oncology Presents Phase 2 Clinical Data on KN046 Combined with Chemotherapy for the Treatment of Advanced NSCLC at ASCO 2021 prnasia
June 07, 2021
Alphamab Oncology announced that data from the Phase II clinical study of the PD-L1/CTLA-4 bispecific antibody KN046 combined with platinum doublet chemotherapy for the treatment of patients with advanced non-small cell lung cancer (NSCLC) is ...
Amgen’s Lumakras Obtains Early FDA Approval for KRAS-Mutated NSCLC drugs
June 01, 2021
At the end of May, FDA approved Amgen’s Lumakras (sotorasib) as the first treatment for adult patients with non-small cell lung cancer (NSCLC) whose tumors have a KRAS G12C genetic mutation and who have received at least one prior systemic therapy.
EU clears Tagrisso for early-stage EGFR-mutated lung cancer pharmatimes
June 01, 2021
The European Commission (EC) has approved AstraZeneca’s (AZ) Tagrisso for the adjuvant treatment of early-stage, epidermal growth factor receptor mutated (EGFR) non-small cell lung cancer (NSCLC) following surgery.
Anti-PD-L1 monoclonal antibody shows promise in lung cancer patient europeanpharmaceuticalreview
May 31, 2021
In a Phase III trial sugemalimab meaningfully improved progression free survival in patients with stage III non-small cell lung cancer (NSCLC).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 20 21 Next page